Sagent Pharmaceuticals (SGNT) Posts Q1 GAAP Loss of 6c/Share

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.06), $0.10 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $82.6 million versus the consensus estimate of $80.63 million.

Sagent Pharmaceuticals sees FY2015 revenue of $325-375 million, versus the consensus of $345.8 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
• LiqTech International (LIQT) Reports In-Line Q2 EPS